Skip to main navigation
Pharvaris N.V logo
Main Menu

Header Nav

  • Our science
  • our pipeline
  • disease focus: HAE
  • HAE community
  • clinical trials
  • About us
    • about us
    • join us
    • Contact
  • Investors
Investor Menu

IR Nav

  • Overview
  • News & Events
    • News Releases
    • Events & Presentations
    • Publications
  • Financials
    • SEC Filings
  • Stock
    • Stock Performance
    • Analyst Coverage
  • Corporate Governance
    • Governance Documents
    • Management Team
    • Board of Directors
    • Committee Composition
  • Resources
    • FAQ
    • Contact Us
    • Email Alerts

Event Details

Breadcrumb

Home / Investor Relations / Events & Presentations / RAPIDe-1 Phase 2 Top-line Data

RAPIDe-1 Phase 2 Top-line Data

Dec 08, 2022 at 8:00 AM EST

Click for Webcast

Supporting Materials

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks 193.1 KB
RAPIDe-1 Phase 2 Top-line Data Presentation 2.2 MB

Toolkit

Print Page
Print Page
Email Alerts
Email Alerts
IR Contacts
IR Contacts

Footer Links

Privacy     Cookie notice     Terms of Use

Social Links

  • Pharvaris 2020 - © All rights reserved